Hepatitis Testing - Market Insights, Competitive Landscape, and Market Forecast - 2034
Description
Hepatitis Testing Market Summary
This hepatitis testing market report offers a comprehensive overview of the global hepatitis testing market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Product Type (Reagents & Kits and Instruments), Technology (Enzyme Linked Immunosorbent Assay (ELISA), Rapid Diagnostic Test, Polymerase Chain Reaction (PCR), Chemiluminescence Immunoassay (CLIA), and Others), Disease Type (Hepatitis B, Heaptitis C, Hepatitis A, Hepatitis D, and Hepatitis E), Test Type (Antigen Test, Antibody Test, Nucleic Acid Test and Genotype Test), End-Users (Hospitals & Clinics, Diagnostic Laboratories, and Others), and Geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing hepatitis testing market.
Hepatitis testing is a set of medical diagnostic procedures used to detect the presence of hepatitis viruses or liver damage caused by them. It typically involves blood tests that identify viral antigens, antibodies, or genetic material (DNA/RNA) to determine whether a person has a current, past, or chronic infection. These tests help in early diagnosis, monitoring disease progression, guiding treatment decisions, and preventing transmission of hepatitis.
The hepatitis testing market is primarily driven by the rising prevalence of hepatitis infections and their severe complications, such as liver cirrhosis and liver cancer, which has increased the need for early diagnosis and routine screening. Additionally, the growth in blood donation and mandatory blood screening programs has significantly increased the demand for hepatitis diagnostic tests to ensure the safety of blood transfusions. Increasing awareness initiatives and national screening programs are also encouraging individuals, particularly high-risk populations, to undergo early testing, thereby supporting market growth. Furthermore, the expanding adoption of point-of-care testing is improving access to rapid and reliable diagnostics, especially in remote and resource-limited settings. At the same time, continuous product development and technological advancements by diagnostic companies, including the introduction of molecular assays, automated immunoassays, and rapid diagnostic kits, are enhancing testing accuracy and efficiency, ultimately driving the overall growth of the hepatitis testing market.
Get More Insights into the Report @Hepatitis Testing Market
What are the latest hepatitis testing market dynamics and trends?
The hepatitis testing market is driven by the rising prevalence of hepatitis B and C and the increasing demand for early diagnosis and routine monitoring.
According to the Centers for Disease Control and Prevention (2025), viral hepatitis had affected more than 300 million people globally.
Additionally, as per the same source, in 2022, 1.2 million people were newly infected with hepatitis B virus (HBV) and 1 million people were newly infected with hepatitis C virus (HCV). Approximately 254 million people were living with chronic hepatitis B, while nearly 50 million people had chronic hepatitis C. As the number of people affected by hepatitis B and C has grown, the demand for early diagnosis, routine screening, and ongoing disease monitoring has increased substantially. Rising infection rates, especially among high-risk populations, have led governments and healthcare providers to expand screening programs and implement targeted public health initiatives. Moreover, the availability of effective antiviral treatments has made early detection essential for timely intervention, further encouraging widespread testing and collectively driving the growth of the hepatitis testing market.
Moreover, India’s National Viral Hepatitis Control Program, which was launched in 2018 with the mission to combat hepatitis and eliminate hepatitis C by 2030, had significantly expanded hepatitis screening and treatment efforts in the country. Reports indicated that by July 2024, the program had screened approximately 10.34 crore individuals for hepatitis B and C and had provided treatment to around 3.3 lakh patients since its inception. As the program has screened millions of individuals for hepatitis B and C, it has created substantial demand for diagnostic tests, reagents, and testing kits used in hospitals, laboratories, and community health centers. Such government-led screening programs encourage routine testing, improve disease detection rates, and expand the use of hepatitis diagnostic technologies, thereby contributing to the overall growth of the hepatitis testing market.
Furthermore, the growth in blood donation and blood screening programs is significantly boosting the hepatitis testing market because all donated blood must be carefully screened to prevent the transmission of infectious diseases such as hepatitis B and hepatitis C. According to the data provided by the World Health Organization (2026), approximately, 118.5 million blood donations were collected globally. Thus, as the number of blood donations increases worldwide, the demand for reliable hepatitis diagnostic tests, including ELISA, nucleic acid testing (NAT), and rapid diagnostic kits, also rises.
However, the increase in product development activities is further boosting the overall market of respiratory care devices. For instance, in June 2024, Cepheid announced that it had received FDA De Novo marketing authorization and Clinical Laboratory Improvement Amendments (CLIA) Waiver approval for Xpert® HCV, making it the only molecular test in the U.S. capable of detecting hepatitis C virus RNA directly from a human capillary whole blood (fingerstick) sample. The Xpert HCV test was performed on the GeneXpert Xpress System.
Thus, the factors mentioned above are expected to boost the overall market of hepatitis testing during the forecast period from 2026 to 2034.
However, the hepatitis testing market encounters several challenges that may hinder its growth. Technical limitations in serological assays, including cross-reactivity, low sensitivity during early infection, or interference from other biological factors, can result in inaccurate or inconclusive outcomes, impacting diagnosis and patient care. Furthermore, the rigorous regulatory approval process requiring extensive clinical validation and adherence to regional and international standards can delay product launches and increase development costs. Collectively, these factors create significant obstacles for manufacturers and healthcare providers, potentially restricting the widespread adoption and timely availability of hepatitis testing solutions.
Hepatitis Testing Market Segment Analysis
Hepatitis Testing Market by Product Type (Reagents & Kits and Instruments), Technology (Enzyme Linked Immunosorbent Assay (ELISA), Rapid Diagnostic Test, Polymerase Chain Reaction (PCR), Chemiluminescence Immunoassay (CLIA), and Others), Disease Type (Hepatitis B, Heaptitis C, Hepatitis A, Hepatitis D, and Hepatitis E), Test Type (Antigen Test, Antibody test, Nucleic Acid Test and Genotype Test), End-Users (Hospitals & Clinics, Diagnostic Laboratories, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
Hepatitis Testing Market Regional Analysis
North America Hepatitis Testing Market Trends
North America is expected to account for the highest proportion of 42% of the hepatitis testing market in 2025, out of all regions. This dominance is fueled by the high prevalence of hepatitis B and C, extensive screening initiatives, well-developed healthcare infrastructure, technological advancements in diagnostics, and mandatory blood donor testing.
According to the Centers for Disease Control and Prevention, in 2023, the United States had recorded 1,643 new cases of hepatitis A, 2,212 new cases of hepatitis B, and 5,538 new cases of hepatitis C. With the global rise in hepatitis B and C infections, the demand for early diagnosis, routine screening, and continuous disease monitoring has grown substantially. High infection rates, particularly among high-risk populations, have led governments and healthcare providers to expand screening programs and implement targeted public health initiatives. Furthermore, the availability of effective antiviral treatments has made early detection crucial, driving wider adoption of testing and collectively fueling growth in the hepatitis testing market.
Moreover, according to Blue Faery: The Adrienne Wilson Liver Cancer Association, in 2024 an estimated 41,630 new cases of liver cancer were reported, including 28,000 cases in men and 13,630 cases in women. Chronic infections caused by Hepatitis B and Hepatitis C are major risk factors for the development of liver cancer. Long-term viral hepatitis can lead to liver inflammation, fibrosis, and cirrhosis, increasing the risk of cancer. As a result, the growing emphasis on early diagnosis and monitoring has increased the demand for advanced diagnostic tools such as serological assays, molecular tests, and rapid diagnostic kits, thereby boosting the hepatitis testing market globally.
However, the increase in product development activities is further boosting the overall market of hepatitis testing. For instance, in June 2024, Cepheid announced that it had received FDA De Novo marketing authorization and Clinical Laboratory Improvement Amendments (CLIA) Waiver approval for Xpert® HCV, making it the only molecular test in the U.S. capable of detecting hepatitis C virus RNA directly from a human capillary whole blood (fingerstick) sample.
Thus, all the above-mentioned factors are anticipated to propel the market for hepatitis testing in North America during the forecast period.
Europe Hepatitis Testing Market Trends
In Europe, the hepatitis testing market is primarily driven by ongoing prevalence of hepatitis B and C infections which has heightened the demand for early detection and routine monitoring. At the same time, technological advancements including molecular diagnostics, automated immunoassays, and rapid point-of-care tests have enhanced both the accuracy and accessibility of hepatitis testing.
According to the European Centre for Disease Prevention and Control, in 2023, the European Union/European Economic Area (EU/EEA) had reported 37,766 cases of hepatitis B virus (HBV) infection, corresponding to a crude rate of 8.1 cases per 100,000 population. Of these cases, 6.3% were classified as acute, 40.5% as chronic, 46.1% as unknown, and 7.1% could not be classified. With the growing number of hepatitis B and C cases, the need for early diagnosis, regular screening, and continuous disease monitoring has risen significantly. The availability of effective antiviral treatments has further emphasized the importance of early detection, driving greater adoption of testing and, in turn, fueling the growth of the hepatitis testing market.
Moreover, according to the International Agency for Research on Cancer, the estimated number of new cases of liver and intrahepatic bile duct cancer in Europe was 91,200 in 2025 and is projected to reach 113,000 by 2045. Early detection of hepatitis infections is essential to prevent progression to severe liver diseases, including liver and bile duct cancers. Growing awareness of this link has led governments and healthcare organizations to implement large-scale screening programs, boosting demand for serological, molecular, and rapid point-of-care tests, and driving growth in the global hepatitis testing market.
Hence, all the factors mentioned above are expected to drive the market for hepatitis testing in Europe during the forecast period.
Asia-Pacific Hepatitis Testing Market Trends
In the Asia Pacific region, the hepatitis testing market is driven by the growing prevalence of hepatitis B and C infections along with increasing government initiatives aimed at early diagnosis and disease control. Moreover, the adoption of advanced diagnostic technologies such as molecular testing and rapid point-of-care assays has improved the accessibility and efficiency of hepatitis detection.
According to the Global Hepatitis Elimination Initiative, the 2022 survey report indicated that the prevalence of chronic HBV infection in Japan was estimated at 0.77%. As per the same source (2023), an estimated 7.6 million people in China were living with chronic hepatitis C. As the number of infected individuals continues to increase, the demand for early diagnosis, routine screening, and continuous disease monitoring has grown significantly. Early detection enables timely initiation of antiviral treatment and helps prevent serious complications such as liver cirrhosis and liver cancer. Consequently, the growing need for early and accurate diagnosis is accelerating the expansion of the hepatitis testing market.
Moreover, according to the International Agency for Research on Cancer, the estimated number of new cases of liver and intrahepatic bile duct cancers in Japan was 390,000 in 2025 and is projected to reach 541,000 by 2045. Long-term hepatitis infections can lead to liver inflammation, cirrhosis, and eventually cancer, which has increased the need for early detection and routine screening of hepatitis viruses. As a result, healthcare providers increasingly conduct hepatitis testing to identify infected individuals at an early stage and monitor disease progression, thereby escalating the overall market of hepatitis testing across the region.
However, the increase in product development activities is further boosting the overall market of hepatitis testing. For example, in October 2025, Reszon Diagnostics International, a subsidiary of Hextar Healthcare and manufacturer of innovative rapid diagnostic tests, launched the RESZON HBsAg Rapid Test commercially. The test provided a fast and reliable method for detecting the Hepatitis B surface antigen (HBsAg) in serum, plasma, or whole-blood samples.
Thus, the factors mentioned above are expected to boost the market of hepatitis testing across the Asia-Pacific region.
Who are the major players in the hepatitis testing market?
The following are the leading companies in the hepatitis testing market. These companies collectively hold the largest market share and dictate industry trends.
The competitive landscape of the hepatitis testing market is shaped by the presence of a mix of global diagnostics leaders and emerging regional players, all striving to innovate and expand their market reach. Established companies such as Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, and Bio-Rad Laboratories dominate through extensive product portfolios that include ELISA kits, molecular assays, and rapid point-of-care tests, supported by strong distribution networks and regulatory approvals across multiple regions. Competition is intensified by continuous technological advancements, with companies investing heavily in next-generation diagnostics that offer higher sensitivity, faster turnaround times, and automation to meet growing clinical demands. Additionally, strategic collaborations, mergers, acquisitions, and partnerships are increasingly being used to expand geographic presence, strengthen R&D capabilities, and improve access to emerging markets. Smaller or regional players focus on niche segments such as affordable rapid tests or specialized molecular kits, creating diverse options for end-users. This dynamic competitive environment drives innovation, improves testing accuracy, broadens product availability, and ultimately shapes the growth trajectory of the global hepatitis testing market.
Overall, the hepatitis testing market is witnessing robust competition, where innovation, compliance, and strategic growth initiatives are the primary factors enabling companies to differentiate themselves, capture market share, and meet the evolving needs of healthcare providers globally.
Recent Developmental Activities in the Hepatitis Testing Market
Instruments
Rapid Diagnostic Test
Chemiluminescence Immunoassay (CLIA)
Polymerase Chain Reaction (PCR)
Others
Hepatitis C
Hepatitis A
Hepatitis D
Hepatitis E
Antibody Test
Nucleic Acid
Genotype Test
Diagnostic Laboratories
Others
AI-Powered Innovations and Applications:
AI‑powered innovations are increasingly influencing the hepatitis testing market by enhancing diagnostic accuracy, operational efficiency, and clinical decision‑making. Artificial intelligence (AI) and machine learning algorithms can analyze complex data from imaging, laboratory results, and patient records to identify patterns that may be difficult for human interpretation alone. In hepatitis testing, AI supports improved interpretation of molecular and serological assay data, reducing false positives and negatives and enabling earlier detection of infection. AI also accelerates workflow automation in high‑volume laboratory environments by optimizing sample processing, result validation, and quality control, which reduces turnaround times and operational costs. When integrated with next‑generation diagnostic platforms, such as digital immunoassays and PCR systems, AI tools help laboratories tailor testing protocols based on patient history and risk factors, improving personalized diagnostics and treatment planning. Additionally, AI facilitates predictive analytics and population health management by identifying trends in hepatitis incidence and testing patterns, enabling health systems to allocate resources more effectively and target screening programs to high‑risk groups. AI‑driven software can also support telemedicine and remote testing interpretations, expanding access in underserved or resource‑limited regions. Overall, the integration of AI into the hepatitis testing ecosystem is enhancing efficiency, accuracy, and scalability, positioning AI as a transformative factor that is likely to support future market growth and innovation.
U.S. Tariff Impact Analysis on Hepatitis Testing Market:
The U.S. tariff impact on the hepatitis testing market centers on how broader trade duties on imported medical and diagnostic products can influence costs, supply chains, and competitive dynamics within the in vitro diagnostics (IVD) sector that includes hepatitis testing kits and related reagents. Since many diagnostic components and complete test kits are produced outside the United States, tariffs on imports—ranging from baseline duties to elevated trade penalties on goods from key manufacturing hubs—can increase the cost of goods sold for companies that rely on foreign production, potentially prompting higher prices for laboratories, clinics, and patients. Diagnostic manufacturers may respond by absorbing costs, relocating manufacturing to the U.S., or shifting supply chains, which could influence product pricing and availability in the hepatitis testing segment. Higher input costs and supply chain disruptions caused by tariffs can also strain operational budgets of healthcare providers by making essential supplies more expensive and less predictable to source, which in turn may affect testing volumes and overall market growth dynamics. Companies with primarily domestic manufacturing could benefit if imported competitors face tariff‑induced cost increases, while ongoing tariff uncertainty may deter investment and complicate long‑term planning for both suppliers and buyers in the hepatitis testing market.
How This Analysis Helps Clients
- The global hepatitis testing market is expected to increase from USD 3,470.08 million in 2025 to USD 5,785.24 million by 2034, reflecting strong and sustained growth.
- The global hepatitis testing market is growing at a CAGR of 5.93% during the forecast period from 2026 to 2034.
- The hepatitis testing market is primarily driven by the rising prevalence of hepatitis infections and their associated risk factors, such as chronic liver disease, lifestyle-related conditions, and high-risk populations. As awareness of early detection grows, healthcare providers are increasingly adopting point-of-care testing, which allows for rapid, on-site diagnosis and timely treatment decisions. Additionally, continuous product development and innovation by diagnostic companies, including the introduction of advanced molecular assays, rapid diagnostic kits, and automated testing platforms, is expanding the availability and efficiency of hepatitis testing, further fueling market growth.
- The leading companies operating in the hepatitis testing market include Abbott, F. Hoffmann-La Roche Ltd., Diasorin S.p.A, Bio-Merieux, Hologic Inc., Danaher Corporation, AdvaCare Pharma, Alpine Biomedicals Pvt Ltd., Siemens Healthineers, SD Biosensor, Inc., OraSure Technologies, Inc., Creative Diagnostics, SSI Diagnsotica A/S, InTec Products, Inc., BTNX Inc., ACON Laboratories, Inc., Altona Diagnostics GmbH, Bruker Corporation, Mikrogen GmbH, Fortress Diagnostics and others.
- North America’s hepatitis testing market is primarily driven by the high prevalence of chronic Hepatitis B and Hepatitis C, which continues to increase the demand for early diagnosis and routine disease monitoring. In addition, technological advancements such as molecular diagnostics, automated immunoassays, and rapid point-of-care testing have significantly improved testing accuracy, efficiency, and accessibility. Mandatory blood donor screening programs and rising public awareness regarding liver health also contribute to sustained testing demand. Collectively, these factors are strengthening and accelerating the growth of the hepatitis testing market across North America.
- In the product type segment of the hepatitis testing market, regents & kits category is estimated to account for the largest market share in 2025.
- Rising prevalence of hepatitis infections and associated risk factors: The hepatitis testing market is strongly fueled by the increasing prevalence of hepatitis infections and their serious complications, such as liver cancer and liver cirrhosis. Chronic infections with Hepatitis B and Hepatitis C can cause progressive liver damage over time, significantly raising the risk of cirrhosis and liver cancer. This growing health burden has created a critical need for early detection and routine screening, enabling timely intervention and better disease management. As a result, there is an increasing demand for advanced hepatitis diagnostic tools, including molecular assays, serological tests, and rapid diagnostic kits, which is driving the overall expansion of the hepatitis testing market globally.
- Growth in blood donation and blood screening programs: The growth in blood donation and blood screening programs is significantly boosting the hepatitis testing market as donated blood must be thoroughly screened to prevent the transmission of infectious diseases such as hepatitis B and hepatitis C. Blood banks and transfusion centers routinely conduct mandatory screening tests to detect hepatitis antigens, antibodies, or viral nucleic acids before blood is approved for transfusion. As the number of blood donations increases due to rising healthcare needs, surgical procedures, and emergency treatments, the demand for reliable hepatitis testing methods such as ELISA, rapid diagnostic tests, and nucleic acid testing (NAT) also increases. In addition, government regulations and public health initiatives that mandate strict blood safety protocols further drive the adoption of hepatitis diagnostic kits and reagents, thereby contributing to the overall growth of the hepatitis testing market.
- Increasing awareness and screening programs: Increasing awareness and screening programs are significantly boosting the hepatitis testing market as governments and healthcare organizations are actively promoting early detection of hepatitis infections. Public health campaigns, community screening initiatives, and national hepatitis control programs encourage people to undergo routine testing, especially high-risk populations. Early diagnosis helps in timely treatment and prevents the spread of the disease, which increases the demand for various hepatitis diagnostic tests such as ELISA, rapid tests, and molecular assays. As a result, the expansion of awareness campaigns and large-scale screening programs is driving the growth of the hepatitis testing market.
- Increasing adoption of point-of-care testing: The growing availability of point-of-care hepatitis testing kits is making diagnostic services more accessible, particularly in developing countries and remote healthcare settings. Rapid diagnostic tests allow healthcare professionals to obtain results within minutes without requiring advanced laboratory infrastructure. This expansion of decentralized testing is helping to increase screening coverage and accelerate market growth.
- Increase in product development activities among key market players: Diagnostic companies are continuously investing in research and innovation to develop advanced testing solutions that are faster, more accurate, and easier to use. This includes the introduction of high-sensitivity molecular assays, rapid diagnostic kits, automated testing platforms, and multiplex testing technologies. Such developments not only improve the efficiency of hepatitis detection but also expand the availability of testing options across hospitals, laboratories, and point-of-care settings. The ongoing focus on innovation by key players is thus enhancing market competitiveness and fueling the overall growth of the hepatitis testing market.
This hepatitis testing market report offers a comprehensive overview of the global hepatitis testing market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Product Type (Reagents & Kits and Instruments), Technology (Enzyme Linked Immunosorbent Assay (ELISA), Rapid Diagnostic Test, Polymerase Chain Reaction (PCR), Chemiluminescence Immunoassay (CLIA), and Others), Disease Type (Hepatitis B, Heaptitis C, Hepatitis A, Hepatitis D, and Hepatitis E), Test Type (Antigen Test, Antibody Test, Nucleic Acid Test and Genotype Test), End-Users (Hospitals & Clinics, Diagnostic Laboratories, and Others), and Geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing hepatitis testing market.
Hepatitis testing is a set of medical diagnostic procedures used to detect the presence of hepatitis viruses or liver damage caused by them. It typically involves blood tests that identify viral antigens, antibodies, or genetic material (DNA/RNA) to determine whether a person has a current, past, or chronic infection. These tests help in early diagnosis, monitoring disease progression, guiding treatment decisions, and preventing transmission of hepatitis.
The hepatitis testing market is primarily driven by the rising prevalence of hepatitis infections and their severe complications, such as liver cirrhosis and liver cancer, which has increased the need for early diagnosis and routine screening. Additionally, the growth in blood donation and mandatory blood screening programs has significantly increased the demand for hepatitis diagnostic tests to ensure the safety of blood transfusions. Increasing awareness initiatives and national screening programs are also encouraging individuals, particularly high-risk populations, to undergo early testing, thereby supporting market growth. Furthermore, the expanding adoption of point-of-care testing is improving access to rapid and reliable diagnostics, especially in remote and resource-limited settings. At the same time, continuous product development and technological advancements by diagnostic companies, including the introduction of molecular assays, automated immunoassays, and rapid diagnostic kits, are enhancing testing accuracy and efficiency, ultimately driving the overall growth of the hepatitis testing market.
Get More Insights into the Report @Hepatitis Testing Market
What are the latest hepatitis testing market dynamics and trends?
The hepatitis testing market is driven by the rising prevalence of hepatitis B and C and the increasing demand for early diagnosis and routine monitoring.
According to the Centers for Disease Control and Prevention (2025), viral hepatitis had affected more than 300 million people globally.
Additionally, as per the same source, in 2022, 1.2 million people were newly infected with hepatitis B virus (HBV) and 1 million people were newly infected with hepatitis C virus (HCV). Approximately 254 million people were living with chronic hepatitis B, while nearly 50 million people had chronic hepatitis C. As the number of people affected by hepatitis B and C has grown, the demand for early diagnosis, routine screening, and ongoing disease monitoring has increased substantially. Rising infection rates, especially among high-risk populations, have led governments and healthcare providers to expand screening programs and implement targeted public health initiatives. Moreover, the availability of effective antiviral treatments has made early detection essential for timely intervention, further encouraging widespread testing and collectively driving the growth of the hepatitis testing market.
Moreover, India’s National Viral Hepatitis Control Program, which was launched in 2018 with the mission to combat hepatitis and eliminate hepatitis C by 2030, had significantly expanded hepatitis screening and treatment efforts in the country. Reports indicated that by July 2024, the program had screened approximately 10.34 crore individuals for hepatitis B and C and had provided treatment to around 3.3 lakh patients since its inception. As the program has screened millions of individuals for hepatitis B and C, it has created substantial demand for diagnostic tests, reagents, and testing kits used in hospitals, laboratories, and community health centers. Such government-led screening programs encourage routine testing, improve disease detection rates, and expand the use of hepatitis diagnostic technologies, thereby contributing to the overall growth of the hepatitis testing market.
Furthermore, the growth in blood donation and blood screening programs is significantly boosting the hepatitis testing market because all donated blood must be carefully screened to prevent the transmission of infectious diseases such as hepatitis B and hepatitis C. According to the data provided by the World Health Organization (2026), approximately, 118.5 million blood donations were collected globally. Thus, as the number of blood donations increases worldwide, the demand for reliable hepatitis diagnostic tests, including ELISA, nucleic acid testing (NAT), and rapid diagnostic kits, also rises.
However, the increase in product development activities is further boosting the overall market of respiratory care devices. For instance, in June 2024, Cepheid announced that it had received FDA De Novo marketing authorization and Clinical Laboratory Improvement Amendments (CLIA) Waiver approval for Xpert® HCV, making it the only molecular test in the U.S. capable of detecting hepatitis C virus RNA directly from a human capillary whole blood (fingerstick) sample. The Xpert HCV test was performed on the GeneXpert Xpress System.
Thus, the factors mentioned above are expected to boost the overall market of hepatitis testing during the forecast period from 2026 to 2034.
However, the hepatitis testing market encounters several challenges that may hinder its growth. Technical limitations in serological assays, including cross-reactivity, low sensitivity during early infection, or interference from other biological factors, can result in inaccurate or inconclusive outcomes, impacting diagnosis and patient care. Furthermore, the rigorous regulatory approval process requiring extensive clinical validation and adherence to regional and international standards can delay product launches and increase development costs. Collectively, these factors create significant obstacles for manufacturers and healthcare providers, potentially restricting the widespread adoption and timely availability of hepatitis testing solutions.
Hepatitis Testing Market Segment Analysis
Hepatitis Testing Market by Product Type (Reagents & Kits and Instruments), Technology (Enzyme Linked Immunosorbent Assay (ELISA), Rapid Diagnostic Test, Polymerase Chain Reaction (PCR), Chemiluminescence Immunoassay (CLIA), and Others), Disease Type (Hepatitis B, Heaptitis C, Hepatitis A, Hepatitis D, and Hepatitis E), Test Type (Antigen Test, Antibody test, Nucleic Acid Test and Genotype Test), End-Users (Hospitals & Clinics, Diagnostic Laboratories, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
Hepatitis Testing Market Regional Analysis
North America Hepatitis Testing Market Trends
North America is expected to account for the highest proportion of 42% of the hepatitis testing market in 2025, out of all regions. This dominance is fueled by the high prevalence of hepatitis B and C, extensive screening initiatives, well-developed healthcare infrastructure, technological advancements in diagnostics, and mandatory blood donor testing.
According to the Centers for Disease Control and Prevention, in 2023, the United States had recorded 1,643 new cases of hepatitis A, 2,212 new cases of hepatitis B, and 5,538 new cases of hepatitis C. With the global rise in hepatitis B and C infections, the demand for early diagnosis, routine screening, and continuous disease monitoring has grown substantially. High infection rates, particularly among high-risk populations, have led governments and healthcare providers to expand screening programs and implement targeted public health initiatives. Furthermore, the availability of effective antiviral treatments has made early detection crucial, driving wider adoption of testing and collectively fueling growth in the hepatitis testing market.
Moreover, according to Blue Faery: The Adrienne Wilson Liver Cancer Association, in 2024 an estimated 41,630 new cases of liver cancer were reported, including 28,000 cases in men and 13,630 cases in women. Chronic infections caused by Hepatitis B and Hepatitis C are major risk factors for the development of liver cancer. Long-term viral hepatitis can lead to liver inflammation, fibrosis, and cirrhosis, increasing the risk of cancer. As a result, the growing emphasis on early diagnosis and monitoring has increased the demand for advanced diagnostic tools such as serological assays, molecular tests, and rapid diagnostic kits, thereby boosting the hepatitis testing market globally.
However, the increase in product development activities is further boosting the overall market of hepatitis testing. For instance, in June 2024, Cepheid announced that it had received FDA De Novo marketing authorization and Clinical Laboratory Improvement Amendments (CLIA) Waiver approval for Xpert® HCV, making it the only molecular test in the U.S. capable of detecting hepatitis C virus RNA directly from a human capillary whole blood (fingerstick) sample.
Thus, all the above-mentioned factors are anticipated to propel the market for hepatitis testing in North America during the forecast period.
Europe Hepatitis Testing Market Trends
In Europe, the hepatitis testing market is primarily driven by ongoing prevalence of hepatitis B and C infections which has heightened the demand for early detection and routine monitoring. At the same time, technological advancements including molecular diagnostics, automated immunoassays, and rapid point-of-care tests have enhanced both the accuracy and accessibility of hepatitis testing.
According to the European Centre for Disease Prevention and Control, in 2023, the European Union/European Economic Area (EU/EEA) had reported 37,766 cases of hepatitis B virus (HBV) infection, corresponding to a crude rate of 8.1 cases per 100,000 population. Of these cases, 6.3% were classified as acute, 40.5% as chronic, 46.1% as unknown, and 7.1% could not be classified. With the growing number of hepatitis B and C cases, the need for early diagnosis, regular screening, and continuous disease monitoring has risen significantly. The availability of effective antiviral treatments has further emphasized the importance of early detection, driving greater adoption of testing and, in turn, fueling the growth of the hepatitis testing market.
Moreover, according to the International Agency for Research on Cancer, the estimated number of new cases of liver and intrahepatic bile duct cancer in Europe was 91,200 in 2025 and is projected to reach 113,000 by 2045. Early detection of hepatitis infections is essential to prevent progression to severe liver diseases, including liver and bile duct cancers. Growing awareness of this link has led governments and healthcare organizations to implement large-scale screening programs, boosting demand for serological, molecular, and rapid point-of-care tests, and driving growth in the global hepatitis testing market.
Hence, all the factors mentioned above are expected to drive the market for hepatitis testing in Europe during the forecast period.
Asia-Pacific Hepatitis Testing Market Trends
In the Asia Pacific region, the hepatitis testing market is driven by the growing prevalence of hepatitis B and C infections along with increasing government initiatives aimed at early diagnosis and disease control. Moreover, the adoption of advanced diagnostic technologies such as molecular testing and rapid point-of-care assays has improved the accessibility and efficiency of hepatitis detection.
According to the Global Hepatitis Elimination Initiative, the 2022 survey report indicated that the prevalence of chronic HBV infection in Japan was estimated at 0.77%. As per the same source (2023), an estimated 7.6 million people in China were living with chronic hepatitis C. As the number of infected individuals continues to increase, the demand for early diagnosis, routine screening, and continuous disease monitoring has grown significantly. Early detection enables timely initiation of antiviral treatment and helps prevent serious complications such as liver cirrhosis and liver cancer. Consequently, the growing need for early and accurate diagnosis is accelerating the expansion of the hepatitis testing market.
Moreover, according to the International Agency for Research on Cancer, the estimated number of new cases of liver and intrahepatic bile duct cancers in Japan was 390,000 in 2025 and is projected to reach 541,000 by 2045. Long-term hepatitis infections can lead to liver inflammation, cirrhosis, and eventually cancer, which has increased the need for early detection and routine screening of hepatitis viruses. As a result, healthcare providers increasingly conduct hepatitis testing to identify infected individuals at an early stage and monitor disease progression, thereby escalating the overall market of hepatitis testing across the region.
However, the increase in product development activities is further boosting the overall market of hepatitis testing. For example, in October 2025, Reszon Diagnostics International, a subsidiary of Hextar Healthcare and manufacturer of innovative rapid diagnostic tests, launched the RESZON HBsAg Rapid Test commercially. The test provided a fast and reliable method for detecting the Hepatitis B surface antigen (HBsAg) in serum, plasma, or whole-blood samples.
Thus, the factors mentioned above are expected to boost the market of hepatitis testing across the Asia-Pacific region.
Who are the major players in the hepatitis testing market?
The following are the leading companies in the hepatitis testing market. These companies collectively hold the largest market share and dictate industry trends.
- Abbott
- F. Hoffmann-La Roche Ltd
- DiaSorin S.p.A
- Bio-Merieux
- Hologic, Inc.
- Danaher Corporation
- AdvaCare Pharma
- Alpine Biomedicals Pvt Ltd
- Siemens Healthineers
- SD Biosensor, Inc.
- OraSure Technologies, Inc.
- Creative Diagnostics
- SSI Diagnostica A/S
- InTec Products, Inc
- BTNX Inc.
- ACON Laboratories, Inc.
- Altona Diagnostics GmbH
- Bruker Corporation
- Mikrogen GmbH
- Fortress Diagnostics
- Others
The competitive landscape of the hepatitis testing market is shaped by the presence of a mix of global diagnostics leaders and emerging regional players, all striving to innovate and expand their market reach. Established companies such as Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, and Bio-Rad Laboratories dominate through extensive product portfolios that include ELISA kits, molecular assays, and rapid point-of-care tests, supported by strong distribution networks and regulatory approvals across multiple regions. Competition is intensified by continuous technological advancements, with companies investing heavily in next-generation diagnostics that offer higher sensitivity, faster turnaround times, and automation to meet growing clinical demands. Additionally, strategic collaborations, mergers, acquisitions, and partnerships are increasingly being used to expand geographic presence, strengthen R&D capabilities, and improve access to emerging markets. Smaller or regional players focus on niche segments such as affordable rapid tests or specialized molecular kits, creating diverse options for end-users. This dynamic competitive environment drives innovation, improves testing accuracy, broadens product availability, and ultimately shapes the growth trajectory of the global hepatitis testing market.
Overall, the hepatitis testing market is witnessing robust competition, where innovation, compliance, and strategic growth initiatives are the primary factors enabling companies to differentiate themselves, capture market share, and meet the evolving needs of healthcare providers globally.
Recent Developmental Activities in the Hepatitis Testing Market
- In December 2025, Altona launched the AltoStar® HDV RT‑PCR Kit 1.5 (CE‑IVD), completing its CE‑IVD PCR portfolio for all five hepatitis viruses.
- In August 2025, HiMedia Laboratories received Central Drugs Standard Control Organisation (CDSCO) approval in India for its Hi‑PCR® Hepatitis B and C molecular diagnostic kits (quantitative), marking a significant milestone for the company’s hepatitis testing portfolio.
- Hepatitis Testing by Product Type Exposure
Instruments
- Hepatitis Testing Technology Exposure
Rapid Diagnostic Test
Chemiluminescence Immunoassay (CLIA)
Polymerase Chain Reaction (PCR)
Others
- Hepatitis Testing Disease Type Exposure
Hepatitis C
Hepatitis A
Hepatitis D
Hepatitis E
- Hepatitis Testing Test Type Exposure
Antibody Test
Nucleic Acid
Genotype Test
- Hepatitis Testing End-Users Exposure
Diagnostic Laboratories
Others
- Hepatitis Testing Geography Exposure
- United States Hepatitis Testing Market
- Canada Hepatitis Testing Market
- Mexico Hepatitis Testing Market
- United Kingdom Hepatitis Testing Market
- Germany Hepatitis Testing Market
- France Hepatitis Testing Market
- Italy Hepatitis Testing Market
- Spain Hepatitis Testing Market
- Rest of Europe Hepatitis Testing Market
- China Hepatitis Testing Market
- Japan Hepatitis Testing Market
- India Hepatitis Testing Market
- Australia Hepatitis Testing Market
- South Korea Hepatitis Testing Market
- Rest of Asia-Pacific Hepatitis Testing Market
- South America Hepatitis Testing Market
- Middle East Hepatitis Testing Market
- Africa Hepatitis Testing Market
AI-Powered Innovations and Applications:
AI‑powered innovations are increasingly influencing the hepatitis testing market by enhancing diagnostic accuracy, operational efficiency, and clinical decision‑making. Artificial intelligence (AI) and machine learning algorithms can analyze complex data from imaging, laboratory results, and patient records to identify patterns that may be difficult for human interpretation alone. In hepatitis testing, AI supports improved interpretation of molecular and serological assay data, reducing false positives and negatives and enabling earlier detection of infection. AI also accelerates workflow automation in high‑volume laboratory environments by optimizing sample processing, result validation, and quality control, which reduces turnaround times and operational costs. When integrated with next‑generation diagnostic platforms, such as digital immunoassays and PCR systems, AI tools help laboratories tailor testing protocols based on patient history and risk factors, improving personalized diagnostics and treatment planning. Additionally, AI facilitates predictive analytics and population health management by identifying trends in hepatitis incidence and testing patterns, enabling health systems to allocate resources more effectively and target screening programs to high‑risk groups. AI‑driven software can also support telemedicine and remote testing interpretations, expanding access in underserved or resource‑limited regions. Overall, the integration of AI into the hepatitis testing ecosystem is enhancing efficiency, accuracy, and scalability, positioning AI as a transformative factor that is likely to support future market growth and innovation.
U.S. Tariff Impact Analysis on Hepatitis Testing Market:
The U.S. tariff impact on the hepatitis testing market centers on how broader trade duties on imported medical and diagnostic products can influence costs, supply chains, and competitive dynamics within the in vitro diagnostics (IVD) sector that includes hepatitis testing kits and related reagents. Since many diagnostic components and complete test kits are produced outside the United States, tariffs on imports—ranging from baseline duties to elevated trade penalties on goods from key manufacturing hubs—can increase the cost of goods sold for companies that rely on foreign production, potentially prompting higher prices for laboratories, clinics, and patients. Diagnostic manufacturers may respond by absorbing costs, relocating manufacturing to the U.S., or shifting supply chains, which could influence product pricing and availability in the hepatitis testing segment. Higher input costs and supply chain disruptions caused by tariffs can also strain operational budgets of healthcare providers by making essential supplies more expensive and less predictable to source, which in turn may affect testing volumes and overall market growth dynamics. Companies with primarily domestic manufacturing could benefit if imported competitors face tariff‑induced cost increases, while ongoing tariff uncertainty may deter investment and complicate long‑term planning for both suppliers and buyers in the hepatitis testing market.
How This Analysis Helps Clients
- Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
- Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
- Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
- Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.
- Market size analysis for the current hepatitis testing market size (2025), and market forecast for 8 years (2026 to 2034)
- Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
- Key companies dominating the hepatitis testing market.
- Various opportunities available for the other competitors in the hepatitis testing market space.
- What are the top-performing segments in 2025? How these segments will perform in 2034?
- Which are the top-performing regions and countries in the current hepatitis testing market scenario?
- Which are the regions and countries where companies should have concentrated on opportunities for the hepatitis testing market growth in the future?
Table of Contents
150 Pages
- 1. Hepatitis Testing Market Report Introduction
- 1.1 Scope of the Study
- 1.2 Market Segmentation
- 1.3 Market Assumption
- 2. Hepatitis Testing Market Executive Summary
- 2.1 Market at Glance
- 3. Hepatitis Testing Market Key Factors Analysis
- 3.1 Hepatitis Testing Market Drivers
- 3.1.1 Rising prevalence of hepatitis infections and associated risk factors
- 3.1.2 Growth in blood donation and blood screening programs
- 3.1.3 Increasing awareness and screening programs
- 3.1.4 Increasing adoption of point-of-care testing
- 3.1.5 Increase in product development activities among key market players
- 3.2 Hepatitis Testing Market Restraints and Challenges
- 3.2.1 Risk of cross-reactivity, low sensitivity during early infection, or interference from other biological factors
- 3.2.2 Stringent regulatory approval process
- 3.3 Hepatitis Testing Market Opportunity
- 3.3.1 Integration of digital health, telemedicine and mobile health technologies in hepatitis testing
- 4. Impact Analysis
- 4.1 AI-Powered Innovations and Applications
- 4.2 U.S. Tariff Impact Analysis
- 5. Regulatory Analysis
- 5.1 The United States
- 5.2 Europe
- 5.3 Japan
- 5.4 China
- 6. Hepatitis Testing Market Porter’s Five Forces Analysis
- 6.1 Bargaining Power of Suppliers
- 6.2 Bargaining Power of Consumers
- 6.3 Threat of New Entrants
- 6.4 Threat of Substitutes
- 6.5 Competitive Rivalry
- 7. Hepatitis Testing Market Assessment
- 7.1 By Product Type
- 7.1.1 Reagents & Kits
- 7.1.2 Instruments
- 7.2 By Technology
- 7.2.1 Enzyme Linked immunosorbent Assay (ELISA)
- 7.2.2 Rapid Diagnostic Test
- 7.2.3 Polymerase Chain Reaction
- 7.2.4 Chemiluminescence Immunoassay
- 7.2.5 Others
- 7.3 By Disease Type
- 7.3.1 Hepatitis B
- 7.3.2 Hepatitis C
- 7.3.3 Hepatitis A
- 7.3.4 Hepatitis D
- 7.3.5 Hepatitis E
- 7.4 By Test Type
- 7.4.1 Antigen Test
- 7.4.2 Antibody Test
- 7.4.3 Nucleic Acid Test
- 7.4.4 Genotype Test
- 7.5 By End-Users
- 7.5.1 Hospitals & Clinics
- 7.5.2 Diagnostic Laboratories
- 7.5.3 Others
- 7.6 By Geography
- 7.6.1 North America
- 7.6.1.1 United States Hepatitis Testing Market Size in USD million (2023-2034)
- 7.6.1.2 Canada Hepatitis Testing Market Size in USD million (2023-2034)
- 7.6.1.3 Mexico Hepatitis Testing Market Size in USD million (2023-2034)
- 7.6.2 Europe
- 7.6.2.1 France Hepatitis Testing Market Size in USD million (2023-2034)
- 7.6.2.2 Germany Hepatitis Testing Market Size in USD million (2023-2034)
- 7.6.2.3 United Kingdom Hepatitis Testing Market Size in USD million (2023-2034)
- 7.6.2.4 Italy Hepatitis Testing Market Size in USD million (2023-2034)
- 7.6.2.5 Spain Hepatitis Testing Market Size in USD million (2023-2034)
- 7.6.2.6 Rest of Europe Hepatitis Testing Market Size in USD million (2023-2034)
- 7.6.3 Asia-Pacific
- 7.6.3.1 China Hepatitis Testing Market Size in USD million (2023-2034)
- 7.6.3.2 Japan Hepatitis Testing Market Size in USD million (2023-2034)
- 7.6.3.3 India Hepatitis Testing Market Size in USD million (2023-2034)
- 7.6.3.4 Australia Hepatitis Testing Market Size in USD million (2023-2034)
- 7.6.3.5 South Korea Hepatitis Testing Market Size in USD million (2023-2034)
- 7.6.3.6 Rest of Asia-Pacific Hepatitis Testing Market Size in USD million (2023-2034)
- 7.6.4 Rest of the World (RoW)
- 7.6.4.1 Middle East Hepatitis Testing Market Size in USD million (2023-2034)
- 7.6.4.2 Africa Hepatitis Testing Market Size in USD million (2023-2034)
- 7.6.4.3 South America Hepatitis Testing Market Size In USD Million (2023-2034)
- 8. Competitive Landscape
- 9. Hepatitis Testing Market Company and Product Profiles
- 9.1 Abbott
- 9.1.1 Company Overview
- 9.1.2 Company Snapshot
- 9.1.3 Financial Overview
- 9.1.4 Product Listing
- 9.1.5 Entropy
- 9.2 F. Hoffmann-La Roche Ltd.
- 9.2.1 Company Overview
- 9.2.2 Company Snapshot
- 9.2.3 Financial Overview
- 9.2.4 Product Listing
- 9.2.5 Entropy
- 9.3 Diasorin S.p.A
- 9.3.1 Company Overview
- 9.3.2 Company Snapshot
- 9.3.3 Financial Overview
- 9.3.4 Product Listing
- 9.3.5 Entropy
- 9.4 Bio-Merieux
- 9.4.1 Company Overview
- 9.4.2 Company Snapshot
- 9.4.3 Financial Overview
- 9.4.4 Product Listing
- 9.4.5 Entropy
- 9.5 Hologic, Inc.
- 9.5.1 Company Overview
- 9.5.2 Company Snapshot
- 9.5.3 Financial Overview
- 9.5.4 Product Listing
- 9.5.5 Entropy
- 9.6 Danaher Corporation
- 9.6.1 Company Overview
- 9.6.2 Company Snapshot
- 9.6.3 Financial Overview
- 9.6.4 Product Listing
- 9.6.5 Entropy
- 9.7 AdvaCare Pharma
- 9.7.1 Company Overview
- 9.7.2 Company Snapshot
- 9.7.3 Financial Overview
- 9.7.4 Product Listing
- 9.7.5 Entropy
- 9.8 Alpine Biomedicals Pvt Ltd
- 9.8.1 Company Overview
- 9.8.2 Company Snapshot
- 9.8.3 Financial Overview
- 9.8.4 Product Listing
- 9.8.5 Entropy
- 9.9 Siemens Healthineers
- 9.9.1 Company Overview
- 9.9.2 Company Snapshot
- 9.9.3 Financial Overview
- 9.9.4 Product Listing
- 9.9.5 Entropy
- 9.10 SD Biosensor, Inc.
- 9.10.1 Company Overview
- 9.10.2 Company Snapshot
- 9.10.3 Financial Overview
- 9.10.4 Product Listing
- 9.10.5 Entropy
- 9.11 OraSure technologies, Inc.
- 9.11.1 Company Overview
- 9.11.2 Company Snapshot
- 9.11.3 Financial Overview
- 9.11.4 Product Listing
- 9.11.5 Entropy
- 9.12 Creative Technologies, Inc.
- 9.12.1 Company Overview
- 9.12.2 Company Snapshot
- 9.12.3 Financial Overview
- 9.12.4 Product Listing
- 9.12.5 Entropy
- 9.13 SSI Diagnostica A/S
- 9.13.1 Company Overview
- 9.13.2 Company Snapshot
- 9.13.3 Financial Overview
- 9.13.4 Product Listing
- 9.13.5 Entropy
- 9.14 InTec Products, Inc.
- 9.14.1 Company Overview
- 9.14.2 Company Snapshot
- 9.14.3 Financial Overview
- 9.14.4 Product Listing
- 9.14.5 Entropy
- 9.15 BTNX Inc.
- 9.15.1 Company Overview
- 9.15.2 Company Snapshot
- 9.15.3 Financial Overview
- 9.15.4 Product Listing
- 9.15.5 Entropy
- 9.16 ACON Laboratories, Inc.
- 9.16.1 Company Overview
- 9.16.2 Company Snapshot
- 9.16.3 Financial Overview
- 9.16.4 Product Listing
- 9.16.5 Entropy
- 9.17 Altona Diagnsotics GmbH
- 9.17.1 Company Overview
- 9.17.2 Company Snapshot
- 9.17.3 Financial Overview
- 9.17.4 Product Listing
- 9.17.5 Entropy
- 9.18 Bruker Corporation
- 9.18.1 Company Overview
- 9.18.2 Company Snapshot
- 9.18.3 Financial Overview
- 9.18.4 Product Listing
- 9.18.5 Entropy
- 9.19 Mikrogen GmbH
- 9.19.1 Company Overview
- 9.19.2 Company Snapshot
- 9.19.3 Financial Overview
- 9.19.4 Product Listing
- 9.19.5 Entropy
- 9.20 Fortress Diagnostics
- 9.20.1 Company Overview
- 9.20.2 Company Snapshot
- 9.20.3 Financial Overview
- 9.20.4 Product Listing
- 9.20.5 Entropy
- 10. KOL Views
- 11. Project Approach
- 12. About DelveInsight
- 13. Disclaimer & Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
